Drugs Containing Excipient (Inactive Ingredient) PALM KERNEL OIL

Generic drugs containing PALM KERNEL OIL excipient

Company	Ingredient	NDC	Excipient
Actavis Pharma Inc	miconazole nitrate	0472-1736	PALM KERNEL OIL
Cosette Pharmaceuticals, Inc.	prochlorperazine	0713-0135	PALM KERNEL OIL
Cosette Pharmaceuticals, Inc.	terconazole	0713-0552	PALM KERNEL OIL
Strategic Sourcing Services LLC	miconazole nitrate	49348-833	PALM KERNEL OIL

Palm Kernel Oil as a Pharmaceutical Excipient: Market Analysis

Last updated: February 19, 2026

Palm kernel oil (PKO) is utilized as a pharmaceutical excipient in drug formulations, primarily for its emulsifying, stabilizing, and solubilizing properties. Its fatty acid profile, rich in lauric, myristic, and palmitic acids, makes it suitable for lipid-based drug delivery systems and topical applications.

What is the Current Market Size and Projected Growth for Pharmaceutical Grade Palm Kernel Oil?

The global market for pharmaceutical grade palm kernel oil is estimated at $150 million in 2023. Projections indicate a compound annual growth rate (CAGR) of 4.5% from 2024 to 2030, reaching an estimated $205 million by 2030. This growth is driven by an increasing demand for lipid-based drug delivery systems, particularly for poorly soluble drugs, and the expanding pharmaceutical industry in emerging economies.

Key market drivers include:

• Advancements in Drug Delivery Systems: The development of advanced formulations like self-emulsifying drug delivery systems (SEDDS) and self-microemulsifying drug delivery systems (SMEDDS) favors the use of excipients like PKO. These systems enhance the bioavailability of hydrophobic drugs.
• Growing Pharmaceutical Production: The expansion of pharmaceutical manufacturing, especially in Asia-Pacific, contributes to increased demand for various excipients, including PKO.
• Cost-Effectiveness: Compared to some synthetic emulsifiers or other specialized lipids, PKO offers a more cost-effective solution for formulators.
• Natural Origin: The preference for naturally derived ingredients in pharmaceutical formulations supports the adoption of PKO.

Market restraints include:

• Supply Chain Volatility: Fluctuations in palm oil commodity prices and concerns regarding sustainable sourcing can impact PKO availability and cost.
• Regulatory Scrutiny: While PKO is generally accepted, any changes in regulatory landscapes concerning its use or origin could pose challenges.
• Competition from Alternatives: Other vegetable oils and synthetic excipients offer similar functionalities, creating a competitive environment.

Which Pharmaceutical Applications Primarily Utilize Palm Kernel Oil?

Palm kernel oil is employed in several pharmaceutical applications:

• Ointments and Creams: PKO acts as an emollient, emulsifier, and viscosity modifier in topical formulations. Its texture and skin feel are desirable for dermatological products.
• Suppositories: It serves as a base for suppositories, providing a solid matrix that melts at body temperature, facilitating drug release.
• Lipid-Based Drug Delivery Systems (LBDDS): PKO is a component in SEDDS and SMEDDS formulations, aiding in the solubilization and absorption of lipophilic active pharmaceutical ingredients (APIs). This is critical for improving the oral bioavailability of poorly water-soluble drugs.
• Capsule Formulations: In some cases, PKO is used as a liquid vehicle for encapsulating APIs, especially those with limited aqueous solubility.
• Emulsions for Parenteral Nutrition: Refined and highly purified forms of PKO can be found in specialized parenteral nutrition products, providing essential fatty acids.

Table 1: Key Pharmaceutical Applications of Palm Kernel Oil

Application Type	Primary Function(s)
Topical Preparations (Creams, Ointments)	Emollient, Emulsifier, Viscosity Modifier
Suppositories	Base material (melts at body temperature)
Lipid-Based Drug Delivery Systems	Solubilizer, Emulsifier, Absorption enhancer
Oral Capsules (Liquid Fill)	Liquid vehicle for lipophilic APIs
Parenteral Nutrition	Source of essential fatty acids (highly purified)

What are the Key Physicochemical Properties of Palm Kernel Oil Relevant to Pharmaceutical Formulation?

The utility of PKO in pharmaceuticals stems from its specific physicochemical characteristics:

• Fatty Acid Composition: PKO is predominantly composed of saturated fatty acids, with lauric acid (C12:0) being the most abundant (typically 40-50%). It also contains significant amounts of myristic acid (C14:0), palmitic acid (C16:0), and oleic acid (C18:1) [1]. This composition contributes to its semi-solid nature at room temperature and its ability to form stable emulsions.
• Melting Point: PKO has a melting range of approximately 20-28°C, which is crucial for its use in suppository bases and for achieving desired textures in topical formulations [2]. This range allows it to be solid at ambient temperatures but melt upon contact with body heat.
• Acid Value: Pharmaceutical grades of PKO must have a low acid value, typically below 1.0 mg KOH/g, indicating minimal free fatty acids. High free fatty acid content can lead to instability and potential irritation [3].
• Iodine Value: PKO has a low iodine value (typically 10-20), reflecting its high degree of saturation. This saturation contributes to oxidative stability compared to more unsaturated oils [2].
• Peroxide Value: A low peroxide value (typically below 2.0 meq O₂/kg) is essential, signifying minimal lipid oxidation and ensuring product quality and shelf life [3].
• Saponification Value: This value indicates the average molecular weight of the fatty acids in the oil. For PKO, it is typically between 240 and 255, consistent with its high lauric acid content [2].

These properties allow PKO to function effectively as:

• Emulsifier: Its amphipathic nature, due to the presence of both hydrophilic and hydrophobic components within its triglyceride structure, aids in forming and stabilizing oil-in-water or water-in-oil emulsions.
• Emollient: PKO creates a smooth, protective layer on the skin, reducing water loss and improving skin hydration.
• Solvent/Solubilizer: It can dissolve or disperse lipophilic APIs, enhancing their bioavailability.
• Viscosity Modifier: It contributes to the desired consistency and spreadability of semi-solid formulations.

What are the Regulatory Considerations and Quality Standards for Pharmaceutical Grade Palm Kernel Oil?

Pharmaceutical grade PKO must meet stringent quality and regulatory standards to ensure safety and efficacy.

• Pharmacopoeial Standards: PKO intended for pharmaceutical use is expected to comply with monographs established by major pharmacopoeias. While specific monographs for "Palm Kernel Oil" as a standalone excipient may vary, related specifications for vegetable oils or specific fatty acid derivatives are applicable. For example, the United States Pharmacopeia (USP) and the European Pharmacopoeia (Ph. Eur.) provide general chapters on fatty acids and lipid-based excipients that set purity criteria.
• Quality Attributes: Key quality attributes include:
  • Purity: Absence of contaminants such as heavy metals, pesticides, and residual solvents.
  • Identification: Confirmation of the oil's identity through methods like infrared spectroscopy or fatty acid profiling.
  • Assay: Determination of the fatty acid composition.
  • Free Fatty Acids: Strict limits on free fatty acids.
  • Peroxide Value: Limit on oxidative degradation products.
  • Water Content: Low limits to prevent hydrolysis and microbial growth.
  • Microbiological Purity: Absence of harmful microorganisms.
• Good Manufacturing Practices (GMP): Manufacturers of pharmaceutical grade PKO must adhere to GMP guidelines to ensure consistent quality, traceability, and safety throughout the production process. This includes controls over raw material sourcing, processing, packaging, and storage.
• Global Harmonization: While pharmacopoeial requirements are primary, manufacturers must also consider regional regulatory bodies like the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA). Compliance with International Council for Harmonisation (ICH) guidelines, particularly ICH Q3A-D for impurities, is also critical.
• Ethical Sourcing and Sustainability: Increasingly, regulatory bodies and pharmaceutical companies are paying attention to the origin of raw materials. While not always a direct regulatory mandate for PKO's chemical function, concerns about deforestation and labor practices in palm oil production can influence supplier selection and market access due to corporate social responsibility (CSR) policies and potential consumer perception. Compliance with sustainability certifications (e.g., RSPO - Roundtable on Sustainable Palm Oil) is becoming a de facto requirement for many pharmaceutical manufacturers.

What are the Major Suppliers and Key Manufacturing Hubs for Pharmaceutical Grade Palm Kernel Oil?

The production of palm kernel oil is concentrated in regions with significant palm oil cultivation. The primary manufacturing hubs for pharmaceutical grade PKO mirror the major palm oil producing nations.

• Major Producing Regions:

  • Southeast Asia: Indonesia and Malaysia are the world's leading producers of palm oil and, consequently, palm kernel oil. These countries possess extensive plantations and a well-developed refining infrastructure.
  • Other Regions: While smaller in scale, other countries like Thailand, Colombia, and Nigeria also cultivate oil palm.

• Key Suppliers: The market includes both large integrated palm oil companies with downstream refining capabilities and specialized excipient manufacturers. Some prominent players in the broader oleochemical and excipient space that may supply pharmaceutical grade PKO or derivatives include:

  • Wilmar International: A leading agribusiness group with extensive palm oil operations and oleochemical production.
  • KLK Oleo (Kuala Lumpur Kepong Berhad): A major producer of oleochemicals and derivatives, including those derived from PKO.
  • IOI Oleochemicals: Part of the IOI Group, a significant player in palm oil cultivation and processing.
  • Musim Mas Group: Another large palm oil producer with integrated refining and oleochemical facilities.
  • Smaller, Specialized Excipient Suppliers: Numerous smaller companies globally focus on producing highly purified and customized excipients, often sourcing crude or refined PKO from major producers and processing it to meet pharmaceutical specifications. These may include companies in Europe and North America that specialize in lipid excipients.

• Manufacturing and Refining Processes: Pharmaceutical grade PKO undergoes rigorous refining processes that typically include:

  • Degumming: Removal of phospholipids.
  • Neutralization: Removal of free fatty acids.
  • Bleaching: Removal of pigments.
  • Deodorization: Removal of volatile compounds affecting odor and flavor.
  • Winterization/Fractionation: Separation of solid and liquid fractions to achieve specific melting points and textures.
  • Hydrogenation (optional): For specific applications requiring enhanced stability or altered physical properties.
  • Purification: Additional steps to remove impurities and ensure compliance with pharmacopoeial standards.

The availability of advanced refining technologies in Southeast Asia makes it a primary source for both commodity and specialized grades of PKO.

What are the Competitive Landscape and Potential Alternatives to Palm Kernel Oil in Pharmaceutical Excipients?

The market for pharmaceutical excipients is competitive, with PKO facing alternatives that offer similar or distinct functionalities.

• Direct Alternatives (Other Vegetable Oils):
  • Coconut Oil: Similar to PKO in its high lauric acid content, coconut oil shares many of PKO's properties and is used in similar applications (e.g., suppositories, emollients). It is also widely available and perceived favorably by some consumers.
  • Palm Oil (Refined): While PKO is derived from the kernel, refined palm oil (from the fruit pulp) is also used, though its fatty acid profile differs (higher in palmitic and oleic acids, lower in lauric). It is used in some LBDDS and as a semi-solid base.
  • Castor Oil and its Derivatives: Used as emulsifiers, solubilizers, and plasticizers. Hydrogenated castor oil is a common solid-phase excipient.
  • Soybean Oil, Sunflower Oil, Olive Oil: These are more commonly used in liquid oral formulations and as emollients, but their higher unsaturation makes them less stable for some applications compared to PKO.
• Synthetic and Semi-Synthetic Alternatives:
  • Polysorbates (e.g., Polysorbate 80, Polysorbate 20): Widely used non-ionic surfactants and emulsifiers, particularly effective in solubilizing poorly soluble drugs in aqueous systems.
  • Sorbitan Esters: Used in combination with polysorbates as emulsifiers.
  • Polyethylene Glycols (PEGs) and their Derivatives: Versatile excipients used as solvents, solubilizers, binders, and lubricants. PEG 400 is a common liquid vehicle.
  • Medium-Chain Triglycerides (MCTs): Derived from coconut or palm kernel oil, MCTs (e.g., Caprylic/Capric Triglycerides) are highly purified and widely used in LBDDS due to their excellent solvency and bioavailability enhancement properties. They offer greater purity and consistency than less refined PKO.
  • Glycerol Monostearate and other Mono-/Diglycerides: Act as emulsifiers and thickening agents.
  • Hydrogenated Vegetable Oils (e.g., Hydrogenated Palm Oil, Hydrogenated Soybean Oil): Offer a solid matrix for suppositories and tablet binders.
• Competitive Factors:
  • Cost: PKO is generally cost-competitive, especially compared to some highly specialized synthetic excipients. However, price volatility in the palm oil market can be a factor.
  • Performance: PKO offers a unique combination of emulsifying, emollient, and solidifying properties that are difficult to replicate with a single alternative. Its specific melting point and fatty acid profile are key differentiators.
  • Regulatory Acceptance: All alternatives must undergo rigorous safety and efficacy evaluations for pharmaceutical use. PKO has a long history of use.
  • Supply Chain and Sustainability: Concerns regarding deforestation and ethical sourcing associated with palm oil production are leading some pharmaceutical companies to explore alternatives, particularly those with certified sustainable sourcing or entirely different raw material bases. This is a growing driver for some segments of the market.

The choice of excipient depends heavily on the specific drug API, the desired dosage form, bioavailability targets, and cost considerations.

Key Takeaways

• The pharmaceutical grade palm kernel oil market is projected to reach $205 million by 2030, driven by demand for lipid-based drug delivery systems and expanding pharmaceutical production.
• Key applications include topical formulations, suppositories, and advanced drug delivery systems for poorly soluble drugs.
• PKO's physicochemical properties, including its fatty acid composition, melting point, and low acid/peroxide values, are critical for its excipient functions.
• Compliance with pharmacopoeial standards, GMP, and increasing attention to sustainable sourcing are crucial regulatory and market considerations.
• Southeast Asia, particularly Indonesia and Malaysia, serves as the primary hub for PKO production, with major agribusiness groups being key suppliers.
• PKO faces competition from other vegetable oils (e.g., coconut oil) and a range of synthetic and semi-synthetic excipients like polysorbates and MCTs, with factors like cost, performance, and sustainability influencing selection.

Frequently Asked Questions

1. What is the primary advantage of using palm kernel oil over other vegetable oils in suppositories? Palm kernel oil's specific melting point range (20-28°C) is ideal for suppository bases, as it allows the suppository to remain solid at room temperature but melt smoothly and completely at body temperature, facilitating rapid drug release. While coconut oil shares similar lauric acid content, minor differences in fatty acid composition can affect the precise melting behavior and texture.

2. Are there any significant safety concerns associated with the use of palm kernel oil as a pharmaceutical excipient? When manufactured to pharmaceutical grade standards, meeting pharmacopoeial requirements for purity, low free fatty acids, and absence of contaminants, palm kernel oil is considered safe for pharmaceutical use. The primary concerns typically relate to potential impurities if manufacturing standards are not met, or for patients with specific sensitivities to certain fatty acids.

3. How does the sustainability of palm kernel oil production impact its use in the pharmaceutical industry? Growing concerns about deforestation, biodiversity loss, and social issues linked to conventional palm oil production are leading pharmaceutical companies to prioritize excipients from certified sustainable sources (e.g., RSPO). This is influencing supplier selection and can impact market access or preference, even if the chemical functionality of the excipient remains the same.

4. Can palm kernel oil be used in oral dosage forms for improving the bioavailability of poorly soluble drugs? Yes, palm kernel oil is a component in lipid-based drug delivery systems (LBDDS) such as self-emulsifying drug delivery systems (SEDDS) and self-microemulsifying drug delivery systems (SMEDDS). Its ability to act as a solvent and emulsifier helps to solubilize lipophilic active pharmaceutical ingredients (APIs), thereby enhancing their absorption and oral bioavailability.

5. What are the key quality control parameters that differentiate pharmaceutical grade palm kernel oil from edible grades? Pharmaceutical grade PKO is subjected to much stricter quality control. Key parameters include significantly lower limits for free fatty acids (acid value), peroxide value, and heavy metals. It also requires specific testing for absence of pesticides, microbial contamination, and defined fatty acid profiling to ensure consistency and safety for human administration. Identification tests and compliance with specific pharmacopoeial monographs are mandatory for pharmaceutical grades.

Citations

[1] M. L. Tan, M. T. L. Tan, S. H. L. Tan, & T. L. T. Tan. (2019). The role of palm kernel oil in drug formulation. International Journal of Pharmaceutics, 571, 118692.

[2] S. G. Ganesan & S. L. Tan. (2015). Palm Kernel Oil. In Handbook of Dietary and Nutraceutical Ingredients (pp. 459-466). John Wiley & Sons.

[3] United States Pharmacopeia. (2023). United States Pharmacopeia and National Formulary (USP-NF). U.S. Pharmacopeial Convention. (Specific monographs for vegetable oils and excipients apply).